celecoxib has been researched along with atorvastatin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cassels, A; Cole, C; Hughes, MA; Lexchin, J; McCormack, JP; Mintzes, B | 1 |
| Khor, TO; Kong, AN; Kopelovich, L; Rao, CV; Reddy, BS; Steele, VE; Wang, CX; Zheng, X | 1 |
| Kopelovich, L; Patlolla, JM; Rao, CV; Reddy, BS; Steele, VE; Swamy, MV | 1 |
| Avila, GE; Conney, AH; Cui, XX; Huang, MT; Kong, AN; Lin, Y; Liu, Y; Patel, J; Paulino, R; Rabson, AB; Reddy, BS; Shih, WJ; Zheng, X | 1 |
| Lin, Y; Reddy, BS; Xiao, H; Yang, CS; Zhang, Q | 1 |
| Kapoor, S | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 1 |
| Xiao, H; Yang, CS | 1 |
| Jin, H; Koo, PT; Tsang, DJ; Xiao, H; Yang, CS; Yang, Z | 1 |
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X | 1 |
| Frank, PG; Lanza-Jacoby, S; Laury-Kleintop, L; Raval, M; Yan, G | 1 |
| Cheng, X; Conney, AH; Cui, XX; Ding, N; Dipaola, RS; Du, Z; Goodin, S; Huang, MT; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Chen, S; Conney, AH; Cui, XX; Dipaola, RS; Goodin, S; He, Y; Huang, H; Li, D; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Brosh, T; Chechik, O; Dolkart, O; Gabet, Y; Liron, T; Maman, E; Somjen, D | 1 |
| Correia, A; Hirvonen, J; Li, W; Liu, D; Mäkilä, E; Salonen, J; Santos, HA; Zhang, H | 1 |
| Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP | 1 |
| Akakpo, PK; Amoakohene, G; Antwi-Adjei, M; Biney, RP; Ekor, M; Henneh, IT; Obese, E; Owusu Agyei, PE; Yahaya, ES | 1 |
2 review(s) available for celecoxib and atorvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
22 other study(ies) available for celecoxib and atorvastatin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antiviral Agents; Atorvastatin; Bibliometrics; Canada; Celecoxib; Cholinesterase Inhibitors; Consumer Product Safety; Disclosure; Donepezil; Drug Industry; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Heptanoic Acids; Humans; Indans; Newspapers as Topic; Oseltamivir; Patient Education as Topic; Piperidines; Pyrazoles; Pyrroles; Raloxifene Hydrochloride; Sulfonamides | 2003 |
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Aspirin; Atorvastatin; Azoxymethane; Carcinogens; Celecoxib; Cell Growth Processes; Colonic Neoplasms; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Pyrazoles; Pyrroles; Rats; Rats, Inbred F344; Sulfonamides | 2006 |
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Apoptosis; Atorvastatin; Caspase 3; Caspases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Poly(ADP-ribose) Polymerases; Pyrazoles; Pyrroles; Sulfonamides | 2006 |
Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Topics: Animals; Apoptosis; Atorvastatin; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |
Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.
Topics: Apoptosis; Atorvastatin; Celecoxib; Cell Cycle; Cell Survival; Colonic Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G1 Phase; GTP-Binding Proteins; HCT116 Cells; Heptanoic Acids; HT29 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; MAP Kinase Kinase 4; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrroles; Resting Phase, Cell Cycle; Signal Transduction; Sulfonamides; Time Factors | 2008 |
Atorvastatin and celecoxib: a future role in cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pyrazoles; Pyrroles; Sulfonamides | 2008 |
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Topics: Acetylcholine; Animals; Atorvastatin; Blotting, Western; Body Weight; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; Drug Combinations; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocardium; Nitric Oxide Synthase Type III; Pulmonary Artery; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfonamides; Survival Analysis; Vasodilator Agents | 2008 |
Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells.
Topics: Atorvastatin; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Chromans; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Polyisoprenyl Phosphates; Pyrazoles; Pyrroles; Sulfonamides; Vitamin E | 2010 |
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Pyrazoles; Pyrroles; Sulfonamides; Vascular Cell Adhesion Molecule-1 | 2010 |
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Progression; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Interleukin-6; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Survivin; Xenograft Model Antitumor Assays | 2014 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Heptanoic Acids; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study.
Topics: Animals; Atorvastatin; Biomechanical Phenomena; Celecoxib; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Pyrazoles; Pyrroles; Random Allocation; Rats, Wistar; Receptors, Prostaglandin E, EP4 Subtype; Rotator Cuff; Sulfonamides; Tendons; Wound Healing | 2014 |
Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy.
Topics: Aluminum Silicates; Atorvastatin; Caco-2 Cells; Celecoxib; Cell Death; Cell Proliferation; Cell Survival; Clay; Colonic Neoplasms; Drug Delivery Systems; Drug Liberation; HT29 Cells; Humans; Hydrogen-Ion Concentration; Microfluidics; Microspheres; Nanotubes; Permeability; Polymers | 2017 |
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolones; Signal Transduction; Spheroids, Cellular | 2021 |
Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia.
Topics: Animals; Atorvastatin; Celecoxib; Cholesterol; Coconut Oil; Disease Models, Animal; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Rats, Sprague-Dawley; Triglycerides | 2021 |